Public Health
Volume 120, Issue 4 , Pages 320-328 , April 2006

An overview of illegal opioid use and health services utilization in Canada

  • S. Popova

      Affiliations

    • Faculty of Social Work, University of Toronto, Toronto, Ont., Canada
    • Centre for Addiction and Mental Health (CAMH), Toronto, Ont., Canada
    • Corresponding Author InformationCorresponding author. Address: Social, Prevention and Health Policy Research Department, Centre for Addiction and Mental Health, 33 Russell Street, Room #T406, Toronto, Ont., Canada M5S 2S1. Tel.: +1 416 535 8501x4558; fax +1 416 260 4156.
    • ,
  • J. Rehm

      Affiliations

    • Department of Public Health Sciences, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada
    • Centre for Addiction and Mental Health (CAMH), Toronto, Ont., Canada
    • ,
  • B. Fischer

      Affiliations

    • Department of Public Health Sciences, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada
    • Centre for Addiction and Mental Health (CAMH), Toronto, Ont., Canada

Received 29 October 2004 ,Revised 29 June 2005 ,Accepted 16 September 2005.

References 

  1. Federal, provincial and territorial advisory committee on population health. Reducing the harm associated with injection drug use in Canada. Ottawa: federal, provincial and territorial advisory committee on population health; 2001.
  2. Fischer B, Rehm J. The case for a heroin substitution treatment trial in Canada. Can J Public Health. 1997;88:367–370
  3. Remis R, Leclerc P, Routledge R, et al. Consortium to characterize injection drug users in Canada (Montreal, Toronto and Vancouver). Final report. Toronto; 1998.
  4. Single E. A socio-demographic profile of drug users in Canada, HIV/AIDS prevention and community action programs of health Canada, 2000.
  5. Remis RS, Bruneau J, Hankins CA. Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(Suppl. 1):S57–S59
  6. Fischer B, Rehm J, Brissette S, et al. Illicit opioid use in Canada—comparing social, health and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health Bull NY Acad Med. 2005;82:250–266
  7. Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction. 2002;97:1383–1394
  8. Hser Y, Hoffman V, Grella C, Anglin M. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58:503–508
  9. United Nations. Investing in drug abuse treatment. A discussion paper for policy makers. New York: Office on Drugs and Crime; 2003.
  10. WHO. The world health report 2002: reducing risks, promotion health life. Geneva: World Health Organization; 2002.
  11. WHO. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: position paper. Geneva: World Health Organization, United nations office on drugs and crime, joint United Nations programme on HIV/AIDS; 2004.
  12. Wall R, Rehm J, Fischer B, et al. The social cost of untreated opiate use. J Urban Health. 2001;77:688–722
  13. Remis R, Millson M, Major C. The HIV epidemic among injection drug users in ontario: the situation in 1997. Ontario: Ontario Ministry of Health; 1997;
  14. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 2001;28:351–357
  15. Fischer B, Medved W, Gliksman L, Rehm J. Illicit opiates in Toronto: a profile of current users. Addict Res. 1999;7:377–415
  16. Millar JS. HIV, hepatitis C, and injection drug use in British Columbia: pay now or pay later? British Columbia provincial health officer, 1998.
  17. Ford PM. Queen's university HIV study group. HIV and hep C seroprevalence and associated risk behaviours in a Canadian prison. HIV/AIDS Policy Law. 1999;4:
  18. Bowker SL, Soskolne CL, Houston SC, Newman SC, Jhangri GS. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in a northern Alberta population. Can J Public Health. 2004;95:188–192
  19. Gossop M, Griffiths P, Powis B, Williamson S. Continuing drug risk behaviour: shared use of injecting paraphernalia among London heroin injectors. AIDS Care. 1997;9:651–660
  20. Haydon E, Fischer B, Rehm J. Social determinants of (illicit) drug use and the HIV/AIDS burden. In:  Fischer B,  Rehm J,  Haydon E editor. Reducing the risks, harms and costs of HIV/AIDS and injection drug use: a synthesis of the evidence base of development of policies and 26 programs. Warsaw: Health Canada/UNAIDS/Canadian International Development Agency; 2003;
  21. Brooner R, King V, Kidorf M, Schmidt CJ, Bigelow G. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:80
  22. Darke S, Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend. 1997;48:135–141
  23. Millson P, Challacombe L, Villeneuve PJ, et al. Self-perceived health among canadian opiate users: a comparison to he general population and to other chronic disease populations. Can J Public Health. 2004;95:99–103
  24. Rehm J. Modes de consommation et repartition des drogues en Suisse. In:  Fahrenkrug H,  Rehm J,  Muller R,  Klingemann H,  Linder R editor. Drogues illegales en suisse 1990–1993. La situation dans les cantons et en Suisse. Zurich: Seismo; 1995;p. 13–34
  25. Meyer RE. The disease called addiction: emerging evidence in a 200-year debate. Lancet. 1996;347:162–166
  26. WHO. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993.
  27. National institutes of health. National consensus development panel on effective medical treatment of opiate addiction. J Am Med Assoc 1998;280:1936–43.
  28. Chitwood D, McBride D, Metsch L, Comerford M, McCoy C. A comparison of the need for health care and use of health care by injection-drug users, other chronic drug users, and nondrug users. Am Behav Sci. 1998;41:1107
  29. Etheridge RM, Hubbard RL, Anderson J, Craddock SG, Flynn PM. Treatment structure and treatment services in the drug abuse treatment outcome study (DATOS). Psychol Addict Behav. 1997;11:244–260
  30. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, et al. Barriers to use of free antiretroviral therapy in injection drug users. J Am Med Assoc. 1998;280:549
  31. Latowsky M, Kallen E. Mainstreaming methadone maintenance treatment: the role of family physician. Can Med Assoc J. 1997;157:395–398
  32. Santolaria-Fernandez FJ, Gomez-Sirvent JL, Gonzalez-Reimers JN. Nutritional assessment of drug addicts. Drug Alcohol Depend. 1995;38:11–18
  33. Weber AE, Yip B, O'Shaughnessy MV, Montaner JS, Hogg RS. Determinants of hospital admission among HIV-positive people in British Columbia. Can Med Assoc J. 2000;162:783–786
  34. McGreary KA, French MT. Illicit drug use and emergency room utilization. Health Serv Res. 2000;35:153–169
  35. Laine C, Hauch WW, Gourevitch MN, Rothman J, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. J Am Med Assoc. 2001;285:2355–2362
  36. Stein MD, Anderson B. Injection frequency mediates health service use among persons with a history of drug injection. Drug Alcohol Depend. 2003;70:159–168
  37. Stein MD, O'Sullivan PS, Ellis P, Perrin H, Wartenberg A. Utilization of medical services by drug abusers in detoxification. J Subst Abuse. 1993;5:187–193
  38. Fischer B, Rehm J, Kirst M, Casas M, Hall W, Krausz M. Heroin assisted treatment as a response to the public health problem of opiate dependence. Eur J Public Health. 2002;12:228–234
  39. Health Canada. Literature review: methadone maintenance treatment. Ottawa: Minister of Public Works and Government Services; 2002.
  40. Hulse GK, English DR, Milne E, Holman CDJ. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999;4:221–229
  41. Ward J, Hall W, Mattick R. Role of methadone maintenance in opioid dependence. Lancet. 1999;353:221–226
  42. Gilchrist VJ. Key informant interviews. In:  Crabtree BF,  Miller WL editor. Doing qualitative research. California: Sage Publications; 1992;
  43. Marshall MN. The key informant technique. Fam Pract. 1996;13:92–97
  44. Heyrman J, Goedhuys J. The multiple key informant survey: a method for the comparison of international qualitative data. European academy of teachers in general practice (EURACT), 2001. Available from. http://euract.org/html/doc012.shtml
  45. Strike C, Urbanoski K, Fischer B, Marsh D, Millson M. Policy changes and the methadone treatment system for opioid dependence in Ontario, 1996 to 2001. J Addict Dis. 2005;24:39–51
  46. Canadian institute for health information. Discharge abstract database abstracting manual (group 12, field 8). Ottawa; 1999.
  47. The college of physicians and surgeons of British Columbia. Annual reports. Vancouver: The College of Physicians and Surgeons of British Columbia, 1995–2005. Available from http://www.cpsbc.ca/cps/physician_resources/publications/annual_reports.
  48. Fischer B. Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. J Public Health Policy. 2000;21:187–210
  49. Millson P. Low threshold methadone maintenance treatment outcomes. Report issue 7. College of Physicians and Surgeons of Ontario; 2003.
  50. UNAIDS. Report on the Global HIV/AIDS Epidemic 2002. Geneva: UNAIDS; 2002.
  51. Single E, Robson L, Rehm J, Xie X. Morbidity and mortality attributable to substance abuse in Canada. Am J Public Health. 1999;89:385–390
  52. Single E, Rehm J, Robson L, Truong MV. The relative risks and etiologic fractions of different causes of death and disease attributable to alcohol, tobacco and illicit drug use in Canada. Can Med Assoc J. 2000;162:1669–1675
  53. Canadian community epidemiology network on drug use (CCENDU). Annual meeting. CCENDU; 2002. Available from: http://www.ccsa.ca/ccendu/pdf/ccendu_meeting-notes_2002_e.pdf.
  54. Brands J, Brands B, Marsh D. The expansion of methadone prescribing in Ontario. Addict Res. 2000;8:485–496
  55. Bell J, Dru A, Fischer B, Levit S, Sarfraz MA. Substitution therapy for heroin addiction. Subst Use Misuse. 2002;37:1149–1178
  56. Strike C, Urbanoski K, Fischer B, Marsh D, Millson P. Increases in methadone maintenance treatment in Ontario, 1996–2001. J Addict Dis. 2005;24:39–51
  57. Farrell M, Neeleman J, Gossop M, et al. A review of the legislation, regulation and delivery of methadone in 12 member states in the European union. Brussels: The European Commission; 1996;
  58. Fischer B, Chin A, Kuo I, Kirst M, Vlahov D. Canadian opiate users’ views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse. 2002;37:495–522
  59. Stancliff S, Myers JE, Steiner S, Drucker E. Beliefs about methadone in an inner-city methadone clinic. J Urban Health. 2002;79:571–578
  60. Farrell M, Hall W. The Swiss heroin trials: testing alternative approaches. Br Med J. 1998;316:639
  61. Ling W, Rawson RA, Compton MA. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs. 1994;26:119–128
  62. van den Brink W, Goppel M, van Ree JM. Management of opioid dependence. Curr Opin Psychiatry. 2003;16:297–304
  63. Buxton J. Vancouver drug use epidemiology Report. Vancouver (BC): Canadian Community Epidemiology Network on Drug Use. 2003 Jul. Available from: http://www.ccsa.ca/ccendu/pdf/report_vancouver_2003.pdf
  64. McPherson D. A framework for action: a four pillars approach to drug problems in Vancouver, Vancouver, 2001.
  65. Wood E, Spittal PM, Small W, et al. Displacement of Canada's largest public illicit drug market in response to a police crackdown. Can Med Assoc J. 2004;170:1551–1556
  66. Kerr T, Wood E, Small D, Palepu A, Tyndall MW. Potential use of safer injecting facilities among injection drug users in Vancouver's Downtown Eastside. Can Med Assoc J. 2003;169:759–763
  67. Bargagli AM, et al. Mortality among problem drug users in Europe: a project of the European monitoring centre for drugs and drug addiction (EMCDDA). Heroin addict related clin problems. vol. 4. 2002;p. 5–12
  68. EMCDDA. Annual report 2003: the state of the drugs problem in the European Union and Norway. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2003.

PII: S0033-3506(05)00263-5

doi: 10.1016/j.puhe.2005.09.010

Public Health
Volume 120, Issue 4 , Pages 320-328 , April 2006

Article Tools